In light of recent studies suggesting that amphetamine (AMPH) increases electrically evoked dopamine release ([DA]
Introduction
Amphetamine (AMPH) is used clinically for the treatment of attention deficit hyperactivity disorder and narcolepsy and is one of the most commonly prescribed psychostimulants (Bartholow, 2010) . Due to high prescription rates and significant abuse potential, stimulants (including AMPH) are commonly used offlabel, with 1.2% of individuals aged Ն12 years in the United States reporting prescription stimulant abuse (Substance Abuse and Mental Health Services Administration, 2008) . AMPH exerts its rewarding and reinforcing effects primarily through its ability to increase extracellular dopamine (DA) levels (Di Chiara and Imperato, 1988) . Although AMPH causes inhibition of DA uptake by competitively binding to the dopamine transporter (DAT), it induces much larger increases in extracellular DA than traditional DAT blockers because of its ability to enter DA terminals, cause the movement of DA out of vesicles, and release DA into the extracellular space via DAT-mediated reverse transport (Fleckenstein et al., 2007; Sulzer, 2011) . In addition to robust elevations in extracellular DA, AMPH-induced movement of DA out of vesicles results in decreased exocytotic release. This phenomenon has been shown repeatedly and has historically been a defining characteristic of AMPH effects on the DA system (Sulzer and Rayport, 1990; Sulzer et al., 1993; Jones et al., 1998 Jones et al., , 1999 John and Jones, 2007) . In contrast, it has been proposed recently that exocytotic DA release may be increased by AMPH (Daberkow et al., 2013) . If AMPH facilitates exocytotic release, this would require a revision of the established mechanisms of AMPH action.
Given the widespread use of AMPH, both clinically and offlabel, it is of critical importance to elucidate its exact mechanisms of action. The large body of AMPH literature which documents decreased exocytotic release as a sine qua non mechanism of AMPH action on the DA system has focused on high concentrations (Sulzer and Rayport, 1990; Sulzer et al., 1993; Jones et al., 1998 Jones et al., , 1999 John and Jones, 2007) , which may not be representative of brain concentrations present after acute administration of the drug in vivo. Thus, we assessed the concentration of AMPH reached in the brain in vivo after systemic administration of the drug via microdialysis and used fast scan cyclic voltammetry (FSCV) in brain slices to determine the effects of AMPH on electrically evoked DA levels ([DA] o ) across a wide range of concentrations that encompassed the levels detected.
We found that concentrations of AMPH reached in vivo augmented [DA] o. Using mice with a genetic deletion of the DAT (DAT-KO), we demonstrated that the augmentation was dependent on the interaction of AMPH with the DAT, suggesting that uptake inhibition, rather than increased exocytotic release, was responsible for the signal enhancement. Together, these findings show that the effects of AMPH on [DA] 
Materials and Methods
Animals. Male DAT-KO mice (Giros et al., 1996) on a C57BL/6J background (bred in house for 10 generations) and WT C57BL/6J mice (The Jackson Laboratory) were maintained on a 12 h light/dark cycle (lights on at 6:00 A.M. lights on; lights off at 6:00 P.M.) with food and water available ad libitum. Male Sprague Dawley rats (Harlan Laboratories) weighing between 400 and 450 g were maintained on a 12 h reverse light/dark cycle (lights on at 3:00 P.M.; lights off at 3:00 A.M.), with food and water available ad libitum. All animals were maintained according to the National Institutes of Health guidelines in Association for Assessment and Accreditation of Laboratory Animal Care-accredited facilities. The experimental protocol was approved by the Institutional Animal Care and Use Committee at Wake Forest School of Medicine.
Microdialysis. All micodialysis experiments were performed in male Sprague Dawley rats. Animals were anesthetized with isoflurane (2-3% in oxygen). Microdialysis guide cannulae (CMA/Microdialysis) were stereotaxically implanted above the nucleus accumbens (NAc) core (anteroposterior, ϩ1.2 mm; lateral, 2.0 mm; ventral, 6.0 mm). Concentric microdialysis probes (2 mm membrane length; CMA/Microdialysis) were inserted the day before recording. The probes were continuously perfused at 1 l/min with artificial CSF (aCSF), pH 7.4, containing the following (in mM): 148 NaCl, 2.7 KCl, 1.2 CaCl 2 , and 0.85 MgCl 2 . Baselines were collected for at least 2 h before administration of an AMPH (1 or 10 mg/kg) intraperitoneal challenge. Brain dialysate samples were collected in 20 min intervals throughout the time course of AMPH effects (200 min after injection).
ELISA. An AMPH ELISA kit (Abnova) was used to measure AMPH in brain dialysate samples from animals injected intraperitoneally with either 1 or 10 mg/kg AMPH. The AMPH standards of the manufacturer and negative and positive controls were run on each plate. A 10 l aliquot of diluted samples was pipetted manually into the plate wells in duplicate. The ELISAs were then run according to the instructions of the manufacturers. The samples were incubated with a 100 l dilution of enzyme (horseradish peroxidase)-labeled AMPH derivative in microplate wells coated with fixed amounts of oriented high-affinity purified polyclonal antibody, and the mixture was incubated at room temperature for 60 min in the dark. After incubation, the plate was washed six times with deionized H 2 O to remove any unbound sample or drug-enzyme conjugate. The chromogenic substrate was then added (100 l/well), and the plate was incubated for 30 min in the dark. After substrate incubation, the reaction was halted with the addition of an acid-based stop solution (100 l/well). The plate was read using a Spectra max plus plate reader equipped with a 450 nm filter (Molecular Devices).
Calibration curves were plotted as log concentration versus the logit of the ratio of the absorbance at each concentration divided by the absorbance of the zero standards. AMPH concentrations were estimated from the calibration curve using the ratio of the mean absorbance of the sample to the mean absorbance of the zero standards.
In vitro voltammetry. All FSCV experiments were performed in male WT or DAT-KO mice. FCSV was used to characterize presynaptic DA release in the NAc core region. A vibrating tissue slicer was used to prepare 400-m-thick coronal brain sections containing the NAc. The tissue was immersed in oxygenated aCSF containing the following (in mM): 126 NaCl, 2.5 KCl, 1.2 NaH 2 PO 4 , 2.4 CaCl 2 , 1.2 MgCl 2 , 25 NaHCO 3 , 11 glucose, and 0.4 L-ascorbic acid, pH was adjusted to 7.4.
Once sliced, the tissue was transferred to testing chambers containing aCSF at 32°C, which flowed at 1 ml/min. A carbon fiber microelectrode (100 -200 M length, 7 m radius) and bipolar stimulating electrode were placed in close proximity in the NAc core. Extracellular DA was recorded by applying a triangular waveform (Ϫ0.4 to ϩ1.2 to Ϫ0.4V vs Ag/AgCl, 400 V/s) to the recording electrode and scanning every 100 ms.
DA release was evoked by one pulse, five pulses at 20 Hz, or 24 pulses at 60 Hz (300 A, 4 ms, monophasic for all stimulations) applied to the tissue every 5 min. These stimulation parameters were selected to model the different in vivo firing patterns of DA neurons; one-pulse stimulations are thought to mimic tonic-like signaling while five-pulse, 20 Hz and 24-pulse, 60 Hz stimulations are thought to mimic phasic-like signaling (Zhang et al., 2009; Daberkow et al., 2013) . One-pulse stimulations were applied to the tissue every 5 min until a stable baseline was established (three collections within 10% variability). Subsequently, fivepulse and 24-pulse stimulations were applied to the slice to establish a baseline at these stimulation parameters. To confirm that the stimulation parameters were not altering [DA] o throughout the experiment, onepulse stimulations were recorded again after each change in the experimental parameters. After predrug measures were taken, either 10 or 100 nM concentrations of AMPH were bath applied to the slice. One-pulse stimulations were repeated until DA levels reached stability (ϳ40 min). After stabilization, the multiple-pulse stimulation parameters were performed as described above. Both the 10 and 100 nM groups were then raised to a 10 M concentration and allowed to stabilize before undergoing an identical stimulation protocol to the one described for the lower doses.
Data analysis. For all analysis of FSCV data, Demon Voltammetry and Analysis software was used (Yorgason et al., 2011) . Recording electrodes were calibrated by recording responses (in electrical current; nanoamperes) to a known concentration of DA (3 M) using a flow-injection system. This was used to convert electrical current to DA concentration. Voltammetric data were reported as [DA] o normalized as a percentage of the predrug, one-pulse stimulation from each slice.
Statistics. GraphPad Prism (version 5; GraphPad Software) was used to statistically analyze datasets and create graphs. Release data were subject to a repeated-measures two-way ANOVA with AMPH and stimulation parameters as the factors. When main effects were obtained ( p Ͻ 0.05), differences between groups were tested using a Bonferroni's post hoc test. AMPH brain concentration time courses were analyzed with a one-way ANOVA. When significant main effects were observed ( p Ͻ 0.05), differences across time were tested using a Tukey's post hoc test.
Results

Extracellular concentrations of AMPH
In rats, after a 1 mg/kg intraperitoneal injection of AMPH, a one-way ANOVA revealed a main effect of time on brain AMPH levels (F (10,30) ϭ 5.184, p Ͻ 0.001; n ϭ 4; Fig. 1A ). Tukey's post hoc analysis revealed that levels were significantly elevated from time 0 at 60 (p Ͻ 0.001), 80 ( p Ͻ 0.01), 100 ( p Ͻ 0.05), and 140 ( p Ͻ 0.05) min after injection. The mean concentration of AMPH at the peak of the time course was 10.25 Ϯ 1.625 nM.
After a 10 mg/kg intraperitoneal injection of AMPH, a oneway ANOVA revealed a main effect of time on AMPH levels (F (11, 35) ϭ 12.68, p Ͻ 0.0001; n ϭ 4; Fig. 1B ). Tukey's post hoc analysis revealed that levels were significantly increased from time 0 at 40 (p Ͻ 0.001), 60 ( p Ͻ 0.001), and 80 ( p Ͻ 0.05) min after injection. The mean concentration of AMPH at the peak of the time course was 197 Ϯ 22.417 nM.
AMPH increased [DA] o at low concentrations and decreased [DA] o at high concentrations in WT mice
Having shown in vivo that extracellular concentrations of AMPH after acute administration are substantially lower than concentrations typically examined in vitro (Sulzer and Rayport, 1990; Sulzer et al., 1993; Jones et al., 1998, 1999), we hypothesized that discrepancies between the study by Daberkow et al. (2013) and previous in vitro literature resulted from differences in extracellular AMPH concentrations and sought to determine the effects of AMPH on [DA] o across a wide range of concentrations that encompass AMPH levels detected during our microdialysis experiment, as well as concentrations used in previous in vitro work. Although brain concentrations of AMPH after acute administration were measured in rats to allow for comparison with previous literature (Daberkow et al., 2013) , the effects of these concentrations were assessed in brain slices from mice to allow for the use of the DAT-KO strain, which is not available in rats.
After bath application of 10 nM AMPH in slices from WT mice, [DA] o was assessed after one pulse, five pulses at 20 Hz, and 24 pulses at 60 Hz stimulations compared with their predrug measurements ( Fig. 2 A, D) Previous in vitro studies examined AMPH concentrations in the 100 nM to 10 M range (John and Jones, 2007; Ferris et al., 2011 Ferris et al., , 2012 Calipari et al., 2013) . Therefore, we examined changes in [DA] o in response to concentrations that are representative of previous in vitro work. Consistent with previous work (Ferris et al., 2012) , a two-way repeated-measures ANOVA revealed that there was no effect of AMPH on [DA] o after bath application of 100 nM concentrations in slices from WT animals (F (1,13) ϭ 0.8135, p ϭ 0.3824; n ϭ 6; Fig. 2 B, E) . Additionally, there was a main effect of stimulation parameters on [DA] o (F (2,13) ϭ 11.34, p ϭ 0.0012) but no interaction between AMPH and stimulation parameters (F (2,13) ϭ 1.639, p ϭ 0.2319).
Consistent with previous in vitro work using highconcentration AMPH, at 10 M concentrations in WT slices, a two-way repeated-measures ANOVA revealed a main effect of AMPH on [DA] o (F (1,21) ϭ 12.74, p ϭ 0.0018; n ϭ 8; Fig. 2C,F (F (1,21) ϭ 6.270, p ϭ 0.0206; n ϭ 8; Fig. 3 A, D) . We then compared the AMPH concentration-response curves for WT and DAT-KO animals to determine differences in AMPH-induced effects on [DA] o between strains (Fig. 4) . After one-pulse stimulations, a two-way repeated-measures ANOVA revealed a main effect of strain (F (1,46) ϭ 16.01, p ϭ 0.0002) and concentration (F (2,46) ϭ 21.37, p ϭ 0.0001) on [DA] o , as well as a significant interaction between AMPH concentration and strain (F (2,46) ϭ 5.218, p ϭ 0.0091; Fig. 4A ). Bonferroni's post hoc analysis revealed a significant difference between strains at 10 nM ( p Ͻ 0.01) and 100 nM ( p Ͻ 0.01) concentrations of AMPH, whereas 10 M was not different. These results suggest that the AMPH-induced increases in [DA] o at low concentrations are a result of the interaction of AMPH with the DAT.
After five-pulse, 20 Hz stimulations, a two-way repeatedmeasures ANOVA revealed a main effect of strain (F (1,48) ϭ Figure 1 . AMPH brain levels after 1 and 10 mg/kg intraperitoneal injection. AMPH levels were quantified in brain dialysate samples over a 200 min period after an intraperitoneal AMPH injection of 1 mg/kg (A) or 10 mg/kg (B). ELISA was used to quantify the levels of AMPH present in samples. A, After 1 mg/kg intraperitoneal injection of AMPH, brain AMPH levels were significantly increased, with the mean peak of AMPH brain concentrations equaling 10.25 Ϯ 1.625 nM. B, A 10 mg/kg intraperitoneal AMPH injection resulted in elevations in AMPH brain levels, with the mean peak concentration equaling 197 Ϯ 22.417 nM. *p Ͻ 0.05 vs time 0; **p Ͻ 0.01 vs time 0; ***p Ͻ 0.001 vs time 0.
8.093, p ϭ 0.0065) and concentration (F (2,48) ϭ 11.33, p ϭ 0.0001) but no interaction (F (2,48) ϭ 2.530, p ϭ 0.0903; Fig. 4B ). Bonferroni's post hoc analysis revealed a significant difference between strains at 10 nM AMPH ( p Ͻ 0.05).
After 24-pulse, 60 Hz stimulations, a two-way repeatedmeasures ANOVA revealed no effect of strain (F (1,47) ϭ 3.482, p ϭ 0.0559) but a main effect of concentration (F (2,47) ϭ 15.50, p ϭ 0.0001), as well as a significant interaction (F (2,47) ϭ 3.904, p ϭ 0.0270; Fig. 4C ). Bonferroni's post hoc analysis revealed a significant difference between strains at the 10 nM concentration of AMPH ( p Ͻ 0.01).
Repeated stimulations do not alter DA release over time
To ensure that the observed changes in [DA] o were AMPH induced and not attributable to repeated high-frequency, multiplepulse stimulations over time, identical stimulation parameters were performed in the absence of AMPH in a separate set of WT and DAT-KO animals. We observed no effect of time on [DA] o in slices from WT (F (1,24) ϭ 0.2624, p ϭ 0.6132; n ϭ 9) or DAT-KO (F (1,15) ϭ 0.3913, p ϭ 0.5410; n ϭ 6) animals (data not shown).
Fenfluramine decreased [DA] o across all concentrations, stimulation parameters, and genotypes
To give additional support to the hypothesis that the effects of AMPH on [DA] o are DAT dependent and independent at low and high concentrations, respectively, we examined the effects of fenfluramine, a serotonin releaser with similar effects on vesicular DA storage but with limited DAT affinity, on [DA] o . Because of the lipophilicity of fenfluramine, it is able to cross the plasma membrane, enter the cell, and interact with DA vesicles without using uptake transporters (Spinelli et al., 1988 In brain slices from WT animals, a two-way repeatedmeasures ANOVA revealed a main effect of fenfluramine across a range of stimulation parameters at 10 nM (F (1,9) ϭ 17.35, p ϭ 0.0024; n ϭ 4; Fig. 5A ), 100 nM (F (1,9) ϭ 8.857, p ϭ 0.0156; n ϭ 4; Similarly, in slices from DAT-KO animals, a two-way repeated-measures ANOVA revealed a main effect of fenflu- Figure 2 . AMPH increases evoked DA at low concentrations and decreases exocytotic release at high concentrations in WT animals. The effect of bath-applied AMPH on evoked DA release was determined over multiple stimulation parameters [one pulse (1p); five pulses (5p) at 20 Hz; 24 pulses (24p) at 60 Hz]. Effects of AMPH were consistent across stimulation parameters for all concentrations. Representative traces of evoked DA release before (predrug; blue) and after bath application of 10 nM (A), 100 nM (B), and 10 M (C) AMPH (black). Group data indicating a significant AMPH-induced increase in DA levels after application of 10 nM (D), but not 100 nM (E), AMPH. F, Group data indicating a significant decrease in DA levels after application of 10 M AMPH. *p Ͻ 0.05 vs predrug; **p Ͻ 0.01 vs predrug.
ramine across a range of stimulation parameters after application of 10 nM (F (1,6) ϭ 10.98, p ϭ 0.0161; n ϭ 3; Fig. 5D ), 100 nM (F (1,6) ϭ 13.03, p ϭ 0.0112; n ϭ 3; Fig. 5E ), and 10 M (F (1,11) ϭ 35.58, p ϭ 0.0001; n ϭ 5; Fig. 5F ) fenfluramine, with decreases in [DA] o . Bonferroni's post hoc analysis revealed a significant fenfluramine-induced decrease in [DA] o at 24-pulse stimulations after 10 nM fenfluramine ( p Ͻ 0.05) and at five-pulse ( p Ͻ 0.05) and 24-pulse ( p Ͻ 0.001) stimulations for 10 M concentrations.
These findings further support the hypothesis that AMPH effects are DAT dependent and independent at low and high concentrations, respectively.
Discussion
Here we demonstrate that AMPH mechanisms differ based on the extracellular concentration of AMPH. Specifically, we found a biphasic effect of AMPH, in which low concentrations in- Figure 3 . AMPH decreases evoked DA levels in DAT-KO animals. The effect of bath-applied AMPH on evoked DA levels was determined over multiple stimulation parameters [one pulse (1p); five pulses (5p) at 20 Hz; 24 pulses (24p) at 60 Hz]. Stimulation parameters had no effect on the pharmacological actions of AMPH. Representative traces of evoked DA release before (predrug; red) and after bath application of 10 nM (A), 100 nM (B), and 10 M (C) AMPH (black). D, Group data indicating AMPH-induced decreases in evoked DA at 10 nM. Although ANOVA revealed a main effect of AMPH on evoked DA levels, Bonferroni's post hoc analysis did not reveal a significant effect at any of the stimulation parameters. E, Group data demonstrating AMPH-induced decreases in DA levels after the application of 100 nM AMPH. F, Group data indicating an AMPH-induced decrease in DA levels at 10 M. **p Ͻ 0.01 vs predrug; ***p Ͻ 0.001 vs predrug. . AMPH-induced increases in evoked DA levels are dependent on the DAT. AMPH was bath applied to brain slices from WT (blue) or DAT-KO (red) animals. Evoked DA levels were determined across a concentration-response curve for AMPH (10 nM, 100 nM, 10 M) and multiple stimulation parameters (one pulse; five pulses at 20 Hz; 24 pulses at 60 Hz). A, Concentrationresponse curve for AMPH after one-pulse stimulations. AMPH-induced increases in DA levels at 10 and 100 nM are dependent on the DAT, whereas AMPH-induced decreases at 10 M are not. B, Concentration-response curve for AMPH after five-pulse stimulations. C, Concentration-response curve for AMPH after 24-pulse stimulations. *p Ͻ 0.05 vs DAT-KO animals; **p Ͻ 0.01 vs DAT-KO animals. The opposite effects of low and high concentrations of AMPH on [DA] o in WT animals may help to explain previous literature demonstrating divergent outcomes of acute AMPH administration on DA-mediated behaviors, in which low doses facilitated performance on attention and learning tasks and high doses disrupted performance (de Wit et al., 2002; Idris et al., 2005) .
AMPH-induced depletion of DA vesicles, resulting in decreased [DA] o , has been shown repeatedly in in vitro studies and is traditionally thought to be a hallmark of AMPH actions (Jones et al., 1998 (Jones et al., , 1999 Fleckenstein et al., 2007; Sulzer, 2011) . Recently, Daberkow et al. (2013) extended these findings, showing that AMPH increased [DA] o in vivo and interpreted the increase as augmented exocytotic release. In an attempt to reconcile the apparent discrepancy between the in vitro and in vivo findings, we determined the extracellular concentrations of AMPH reached in vivo to allow the selection of physiologically relevant concentrations to assess in vitro.
We found that, in rats, 1 and 10 mg/kg intraperitoneal injections of AMPH correspond to peak concentrations of ϳ10 and 200 nM AMPH in the extracellular space, respectively. Increases in [DA] o shown in vivo (Daberkow et al., 2013) were measured 10 min after AMPH injection. The time course of AMPH brain concentrations shows that, at this time point, AMPH levels were ϳ30 nM, and our in vitro data suggest that this concentration would produce an increase in [DA] o , similar to the effect demonstrated in vivo. At the time when higher concentrations were observed (40 min), [DA] o is returning to baseline in vivo, which is consistent with effects seen at the concentrations (ϳ100 -300 nM) applied here and in previous studies (Ferris et al., 2012; Calipari et al., 2013 Ferris et al., 2012) , which is higher than the range of concentrations reached in vivo (Daberkow et al., 2013) . We showed that AMPH does facilitate [DA] o in vitro at low concentrations, demonstrating that the discrepancies between the two models are indeed attributable to different extracellular concentrations of AMPH. Although methamphetamine has been shown previously to exhibit similar concentration-dependent effects on DA cell bodies in the midbrain (Branch and Beckstead, 2012) , this is the first examination of the effects of low AMPH concentrations in the terminal regions.
Furthermore, our data show that the biphasic, concentrationdependent effects of AMPH involve both DAT-dependent and -independent mechanisms. Using DAT-KO mice, it was determined that the DAT was required for AMPH-induced increases in [DA] o . AMPH-induced increases are completely absent in DAT-KO animals, demonstrating that AMPH acts via the DAT to elevate [DA] o . Although AMPH enters the cell primarily via transporter-mediated movement (Bönisch, 1984) , it is highly lipophilic and readily traverses the cell membrane (Thoenen et al., 1968; Liang and Rutledge, 1982) . Thus, differences between DAT-KO and WT animals are likely not attributable to a differential ability of AMPH to enter the cell. This is highlighted by the reductions in [DA] o in DAT-KO mice at high concentrations, an effect that demonstrates that vesicular depletion is independent of AMPH actions at the DAT. The hypothesis that AMPH effects at low and high concentrations are DAT dependent and independent, respectively, was further supported by our findings that fenfluramine, an AMPH-like releaser with low DAT affinity, decreased [DA] o across all concentrations. However, in DAT-KO mice, although AMPH is likely causing the movement of DA from vesicles into the cytoplasm, this DA is not released into the extracellular space, and the reduction in [DA] o may be a combi- Figure 5 . Fenfluramine decreases evoked DA levels across all concentrations, stimulation parameters, and genotypes. Fenfluramine was bath applied to brain slices from WT (A-C) or DAT-KO (D-F ) animals. Evoked DA levels were determined across a concentration-response curve for fenfluramine (10 nM, 100 nM, 10 M) and multiple stimulation parameters [one pulse (1p); five pulses (5p) at 20 Hz; 24 pulses (24p) at 60 Hz]. In WT animals, fenfluramine reduced DA levels across all stimulation parameters after 10 nM (A), 100 nM (B), and 10 M (C) concentrations. Although ANOVA revealed a main effect of fenfluramine on evoked DA levels at 100 nM, Bonferroni's post hoc analysis did not reveal a significant effect at any of the stimulation parameters. In DAT-KO animals, DA levels were decreased across all stimulation parameters after 10 nM (D), 100 nM (E), and 10 M (F ) concentrations of fenfluramine. Although ANOVA revealed a main effect of fenfluramine on evoked DA levels at 100 nM, Bonferroni's post hoc analysis did not reveal a significant effect at any of the stimulation parameters. *p Ͻ 0.05 vs predrug; ***p Ͻ 0.001 vs predrug.
nation of vesicular depletion and subsequent degradation of DA that has accumulated within the cytoplasm.
The DAT-dependent and -independent effects observed here suggest that AMPH acts as a DA uptake inhibitor at low concentrations, whereas at high concentrations, vesicular depletion is also present. In voltammetric measurements, as in the brain, the maximal extracellular concentration of DA is a result of the opposing processes of release and uptake; thus, increases in [DA] o , as seen in the current study and previous work (Daberkow et al., 2013) , can be attributed to either increased release or uptake inhibition (Wightman et al., 1990; Yorgason et al., 2011 (Sulzer and Rayport, 1990; Sulzer et al., 1993) . One hypothesis is that AMPHinduced depletion of DA vesicles at high concentrations is a result of AMPH entering vesicles via diffusion across the vesicular membrane or transport through the vesicular monoamine transporter-2 (VMAT-2), where its properties as a weak base disrupt pH gradients, leading to the movement of DA out of vesicles and into the cytoplasm (Fleckenstein et al., 2007; Sulzer, 2011) . The lack of DA depletion observed here in WT mice at low concentrations may be a result of insufficient concentrations of AMPH within the vesicles to disrupt vesicular sequestration. Indeed, previous cell culture studies demonstrated that, at low to moderate concentrations of AMPH, pH gradients are 90% intact (Floor and Meng, 1996) and do not result in movement of DA out of vesicles (Teng et al., 1998) . Thus, AMPH primarily acts as an uptake inhibitor at low concentrations, making its actions resemble those of a blocker.
An alternative, although not opposing, hypothesis is that high AMPH concentrations reduce quantal size by decreasing DA uptake into vesicles via blockade of VMAT-2, resulting in decreased [DA] o (Wallace and Connell, 2008) . Although AMPH may be interacting with VMAT-2 even at the low concentrations tested here, it is likely that effects at the DAT will predominate at these concentrations because the K i of AMPH for the inhibition of DA uptake at the DAT is 34 nM compared with 2.71 M at the VMAT-2 (Philippu and Beyer, 1973; Rothman and Baumann, 2003) . Thus, it is likely that, at low concentrations, AMPH is inhibiting DA uptake at the DAT but having minimal effects on the VMAT-2, resulting in increased [DA] o . However, as concentrations are increased, blockade of the VMAT-2 becomes more prominent, resulting in decreased [DA] o .
Additionally, [DA] o was reduced at low and moderate concentrations in DAT-KO animals. As discussed above, the current findings and previous studies indicate that the AMPH concentrations tested here are not sufficient to decrease exocytotic release. One explanation is that DAT-KO terminals, which are unable to take up DA from synapses and repackage it into vesicles and are therefore dependent on DA synthesis for release, have reduced [DA] o at low concentrations due to the effects of AMPH on DA synthesis (Sotnikova et al., 2006) . It is possible that AMPH raises cytoplasmic DA levels via blockade of the VMAT-2, resulting in substrate inhibition of tyrosine hydroxylase. Cytoplasmic DA buildup may occur in this situation for two reasons: (1) the lack of DAT-mediated reverse transport of DA into the synapse in these animals; and (2) the inhibitory effects of AMPH on monoamine oxidase activity (Sulzer, 2011) . Regardless, both scenarios would likely lead to an increased inhibition of tyrosine hydroxylase activity and subsequent reductions in [DA] o because of the dependence of DAT-KO mice on synthesis of new DA for release.
Here we show biphasic, concentration-dependent actions of AMPH, which suggest that AMPH acts as a blocker at low concentrations and a releaser at high concentrations, making concentration a critical determinant of the acute effects of the compound. This is particularly relevant when considering the neurochemical outcomes of human AMPH use, because lowdose therapeutic and high-dose abuse-relevant administration may have different mechanisms of acutely elevating DA levels, potentially leading to different long-term consequences. Given the shift in mechanism of AMPH from blocker to releaser, depending on concentration, it will be important to amend, but not discard, the traditional view of AMPH mechanisms and its effects on DA neurotransmission.
